These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37569668)

  • 1. Perspectives of Cell Sensitivity/Resistance Assay in Soft Tissue Sarcomas Chemotherapy.
    Fetisov TI; Khazanova SA; Shtompel PA; Trapeznikova ES; Zinovieva VY; Marshall VI; Lovenger AA; Rogozhin DV; Anastasia TA; Bokhyan BY; Belitsky GA; Yakubovskaya MG; Kirsanov KI
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
    Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
    Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
    Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
    Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
    Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
    Goy BW; Syed S; Padmanabhan A; Burchette RJ; Helmstedter CS
    Radiother Oncol; 2021 Dec; 165():174-178. PubMed ID: 34758339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin.
    Kirilin EM; Fetisov TI; Moiseeva NI; Lesovaya EA; Laletina LA; Makhmudova LF; Manikaylo AE; Fomina LY; Burov DA; Bokhyan BY; Zinovieva VY; Vilkova AS; Mekheda LV; Kozlov NA; Scherbakov AM; Belitsky GA; Švedas V; Kirsanov KI; Yakubovskaya MG
    Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Multiple Drug Resistance Mechanism in Different Types of Soft Tissue Sarcomas: Assessment of the Expression of ABC-Transporters, MVP, YB-1, and Analysis of Their Correlation with Chemosensitivity of Cancer Cells.
    Moiseeva NI; Laletina LA; Fetisov TI; Makhmudova LF; Manikaylo AE; Fomina LY; Burov DA; Lesovaya EA; Bokhyan BY; Zinovieva VY; Vilkova AS; Mekheda LV; Kozlov NA; Scherbakov AM; Kirilin EM; Belitsky GA; Yakubovskaya MG; Kirsanov KI
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
    Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
    Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
    BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
    Higuchi T; Miyake K; Sugisawa N; Oshiro H; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Lett; 2019 Jun; 451():122-127. PubMed ID: 30867142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.
    Siurala M; Bramante S; Vassilev L; Hirvinen M; Parviainen S; Tähtinen S; Guse K; Cerullo V; Kanerva A; Kipar A; Vähä-Koskela M; Hemminki A
    Int J Cancer; 2015 Feb; 136(4):945-54. PubMed ID: 24975392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
    Italiano A; Toulmonde M; Bui-Nguyen B
    Bull Cancer; 2010 Jun; 97(6):679-86. PubMed ID: 20483708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study.
    Tian Z; Wang J; Yang J; Zhang P; Wang X; Zhang F; Li P; Yao W
    Invest New Drugs; 2021 Dec; 39(6):1724-1731. PubMed ID: 34156595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
    Leyvraz S; Bacchi M; Cerny T; Lissoni A; Sessa C; Bressoud A; Hermann R
    Ann Oncol; 1998 Aug; 9(8):877-84. PubMed ID: 9789611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX).
    Sundby Hall K; Bruland ØS; Bjerkehagen B; Zaikova O; Engellau J; Hagberg O; Hansson L; Hagberg H; Ahlström M; Knobel H; Papworth K; Zemmler M; Goplen D; Bauer HCF; Eriksson M
    Eur J Cancer; 2018 Aug; 99():78-85. PubMed ID: 29929092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group.
    Tanaka K; Ozaki T
    Jpn J Clin Oncol; 2022 May; 52(6):526-530. PubMed ID: 35292817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
    Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
    Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
    Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
    Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Treatment for Adults with Synovial Sarcoma.
    Desar IME; Fleuren EDG; van der Graaf WTA
    Curr Treat Options Oncol; 2018 Mar; 19(2):13. PubMed ID: 29516254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.